– USA, CA – Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology, today announced the appointment of Faheem Hasnain as CEO and President, effective immediately, succeeding Dr. Sheila Gujrathi who will continue in an advisory role.
Mr. Hasnain is a Co-Founder, former CEO, and current Chairman of Gossamer Bio.
“I would like to thank Sheila for her invaluable contributions to Gossamer Bio, from the founding of the Company to the significant progress we have made across our pipeline, and we wish her best of luck as she moves on to new endeavors,” said Mr. Hasnain. “I am extremely excited to lead the Gossamer Bio team as we continue to advance our pipeline and work to develop important new therapies with tremendous potential to benefit high unmet need patient populations.”
“I am very grateful for having had the opportunity to build and lead a world-class Gossamer Bio team. I am proud of what we have achieved together advancing our innovative research and development programs and look forward to the future success of the Company,” said Dr. Gujrathi.
About Faheem Hasnain
Prior to co-founding Gossamer Bio, Mr. Hasnain served as President, CEO, and as Director of Receptos, Inc. from November 2010 to August 2015. Receptos was a public company formed in 2009 focused on developing treatments in immunology and metabolic disorders and was purchased by Celgene Corporation in August 2015. Previously, Mr. Hasnain was the President and CEO and a director of Facet Biotech Corporation, a biology-driven antibody company with a focus on multiple sclerosis and oncology. He held that position from December 2008 until the company’s acquisition by Abbott Laboratories in April 2010.
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.
For more information: https://www.gossamerbio.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.